Intensity Therapeutics, Inc. (INTS)
Develops cancer drugs injected directly into tumors to stop spread and recurrence.
$4.55+0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-23.8%
The outlook
INTS is trading near its 52-week low, about 3% of the way up from bottom to top. Analyst coverage leans bullish with an average price target roughly 445% above current levels, though the stock sits mixed against its moving averages. Overall sentiment skews bearish at 35/100.
What’s behind the score
Price trendMixed vs its moving averages
52-week range3% of the way from its 52-week low to high
Price targetAvg target +445% vs current price
Analyst price target
~12-month · 5 analysts$24.80average target+445.1% vs now
Now $4.55
Low $12.00High $32.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$12.3M
52-wk high
$43.50
52-wk low
$3.51
50-day avg
$4.33
200-day avg
$7.44
Trailing P/E
—